linjc16/ctgov huggingface dataset:
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Study Overview
=================
Brief Summary
-----------------
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

Detailed Description
-----------------
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer . We will analysis 100 met exon 14 skipping advanced non-small cell lung cancer who treated with crizotninb or chemotherapy for PFS and OS.

Official Title
-----------------
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology Met Exon 14 Skipping First Diagnosis and Treatment Treatment Plan is Crizotinb or Standard Chemotherapy Exclusion Criteria: Patients received antitumor treatment before Patients with contraindication of chemotherapy Pregnant or breast feeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression free survival time | may 2020- may 2021 (1 year) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Over survival time | may 2020- may 2021 (1 year) | 
| ORR | Objective response rate | may 2020- may 2021 (1 year) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crizotinb, non-small cell lung cancer, Chemotherapy
A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome

Study Overview
=================
Brief Summary
-----------------
In this study, we will compare the degree of postoperative symptom improvement, postoperative complication rate, postoperative quality of life improvement degree of patients with Meige syndrome undergoing pallidotomy (unilateral globus palliotomy) and deep brain stimulation (unilateral globus pallidus) ,in order to get the conclusion of the comparison of the clinical efficacy of the two surgical plans. In addition, possible predictive factors such as age, gender, age of onset, length of disease course, scale baseline score, preoperative brain PET-CT function analysis and other possible predictive factors are added for analysis, in order to find predictive factors that can guide the choice of surgical options.

Official Title
-----------------
A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome

Conditions
-----------------
Meige Syndrome, Meigs Syndrome, Meige Disease, Meig Syndrome, Blepharospasm, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm of Both Eyelids, Blepharospasm Oromandibular Dystonia

Intervention / Treatment
-----------------
* Procedure: pallidotomy
* Procedure: deep brain stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients confirmed Meige sydrome Exclusion Criteria: Patients who cannot finish the neurosurgery or the postoperative evaluation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Meige sydrome patients<br> | Procedure: pallidotomy<br>* deep brain nuclei lesion of GPi<br>Procedure: deep brain stimulation<br>* deep brain stimulation of GPi<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom | spasm of eyelid | 2 years | 
| complications | Postoperative complications | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life | Evaluate using SF-36 | 2 years | 
| depression scale | Evaluate using Hamilton Depression Scale | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
deep brain stimulation, DBS, DBNL, GPi, pallidotomy
Clinical and Radiological Outcomes of Medacta Shoulder System

Study Overview
=================
Brief Summary
-----------------
This is a post-marketing surveillance on Medacta Shoulder System

Official Title
-----------------
Clinical and Radiological Outcomes of Medacta Shoulder System

Conditions
-----------------
Primary Osteoarthritis, Secondary Osteoarthritis, Rotator Cuff Tear Arthropathy, Rheumatoid Arthritis Shoulder, Avascular Necrosis, Fracture, Revision of Shoulder Arthroplasty

Intervention / Treatment
-----------------
* Device: Medacta Shoulder System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years Patient with one of the following diagnosis: Primary osteoarthritis Secondary osteoarthritis Cuff tear arthropathy; insufficient rotator cuff Acute fracture (<21d) Rheumatoid or inflammatory arthritis Avascular necrosis Other posttraumatic condition Revision of shoulder arthroplasty Exclusion Criteria: Patients with malignant diseases (at the time of surgery) Patients with proven or suspect infections (at the time of surgery) Patients with functional deficits other than dysfunction of the shoulder (at the time of surgery) Patients with known incompatibility or allergy to products materials (at the time of surgery)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Medacta Shoulder System|Total Shoulder Arthroplasty|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival rate | Kaplan Meier method | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical outcome | Constant & Murley Score | 1, 2, 5 and 10 years | 
| Functional outcome | Oxford Shoulder Score | 1, 2, 5 and 10 years | 
| Radiographic performance of the implants | presence of radiolucencies | 3 months, 1, 2, 5 and 10 years | 
| Quality of life | EQ-5D | 1, 2, 5 and 10 years | 
| Adverse events | record of adverse event | up to 10 years |
The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma

Study Overview
=================
Brief Summary
-----------------
The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.

Official Title
-----------------
Bone Marrow Cytology, Pathology and 18F-FDG PET/CT and Pelvic MRI in the Diagnosis of Lymphoma Bone Marrow Invasion

Conditions
-----------------
Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist. Patients who gave written informed consent were referred for MRI. Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging). Exclusion Criteria: • Pregnancy, general contraindications to MRI.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis | MRI-positive lesions that cannot be confirmed by bone marrow cytology and pathology will be confirmed by MRI follow-up. | Within 30 days prior to start of chemotherapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Agreement Between MRI and 18F-FDG PET/CT at Diagnosis | Region based agreement (%; kappa value) of MRI with 18F-FDG PET/CT at diagnosis. | Within 30 days prior to start of chemotherapy |
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

Study Overview
=================
Brief Summary
-----------------
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.

Official Title
-----------------
Real-world Comparative Effectiveness of Dabigatran Versus VKA

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: Dabigatran (Pradaxa)
* Drug: Vitamin K antagonist


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-valvular atrial fibrillation will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD-9 427.31 (International Classification of Disease, Ninth Revision, Clinical Modification) as the diagnosis code at any time in the patient's data history prior to inclusion Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics CHA2DS2-Vasc (Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65-74 years; Sc: Sex category ) score ≥2 during the 180 days prior to index dabigatran use baseline period Exclusion Criteria: Patients <18 years of age Patients with valvular Atrial fibrillation Pregnancy Malignant cancers Transient cause of Atrial fibrillation Patients with Venous thromboembolism (pulmonary embolism or Deep Vein Thrombosis) Patients with major surgery defined as hip or knee replacement Prescriptions of Oral anticoagulants (OACs) {apixaban, warfarin, dabigatran, rivaroxaban} before index date Prescription of more than one OAC on the index date Patient with any of the events defined in the composite endpoint

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dabigatran<br>Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention. | Drug: Dabigatran (Pradaxa)<br>* As prescribed by treating physicians<br>|
| Vitamin K antagonist<br>Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention. | Drug: Vitamin K antagonist<br>* As prescribed by treating physicians<br>* Other names: As prescribed by treating physicians;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Hospitalization Events (composite endpoint) |  | Within 2 years of starting treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-valvular atrial fibrillation (NVAF), Prevention, Stroke
Volatile Versus Propofol Anesthesia in OPCAB

Study Overview
=================
Brief Summary
-----------------
Off pump coronary artery bypass graft (OPCAB) still requires myocardial protection owing to intermittent regional ischemic episode. The investigators retrospectively evaluated the cardioprotective and clinical outcomes of propofol versus isoflurane anesthesia in patients undergoing OPCAB.

Detailed Description
-----------------
Several experimental and clinical researches have suggested that volatile anesthetics may reduce mortality in cardiac surgery owing to its preconditioning induced cardioprotective effect. Off-pump coronary artery bypass graft (OPCAB) surgery still requires cardioprotective strategies due to coronary hypoperfusion during anastomosis. The aim of this study was to evaluate the possible cardioprotective effect and clinical outcomes of propofol versus isoflurane anesthesia in patients undergoing OPCAB using propensity matching.

Official Title
-----------------
Comparison of Propofol and Isoflurane Anesthesia on Cardioprotection and Clinical Outcomes in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery : A Propensity-score Analysis

Conditions
-----------------
Off Pump Coronary Artery Bypass Graft

Intervention / Treatment
-----------------
* Drug: Isoflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OPCAB Exclusion Criteria: On pump conversion

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Isoflurane group<br>Isoflurane inhalational anesthesia during OPCAB | Drug: Isoflurane<br>* Comparison between isoflurane and propofol, Retrospective study<br>* Other names: inhalational anesthetics;|
| Propofol group<br>Total intravenous anesthesia with propofol during OPCAB | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CK-MB, CRP | Comparison of CK-MB and CRP values between propofol and isoflurane groups on postoperative day, POD1 and POD 2 | Change from preoperative value in CK-MR and CRP at Postoperative day(POD), POD 1 and 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical adverse outcomes | clinical adverse outcomes until postoperative 1 year | until 1 year after OPCAB | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ischemic heart disease, Off pump coronary artery bypass graft, Isoflurane, Propofol
EBIS: The Eindhoven Breech Intervention Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether successful external cephalic version is associated with maternal thyroid function and mood state in pregnant women with breech presentation at term. The relationship between successful external cephalic version and neonatal thyroid function will also be investigated. A possible beneficial effect of successful external cephalic version on the development of congenital hip dysplasia will be evaluated.

Official Title
-----------------
Ebis: The Eindhoven Breech Intervention Study

Conditions
-----------------
Breech Presentation, External Cephalic Version, Thyroid Hormones, Stress, Psychological, Congenital Hip Dysplasia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single pregnancy Gestation of 35 weeks or more Appropriate knowledge of the Dutch language Fetus in any of the 4 types of breech presentation: frank breech, complete breech, incomplete breech or footling presentation Exclusion Criteria: Previous caesarean section Indication for caesarean delivery irrespective of presentation Previous abruptio placenta Multiple pregnancy Ruptured membranes Non-reassuring fetal monitoring tests results Hyperextended fetal head Significant uterine or fetal anomaly Use of thyroid medication Maternal autoimmune disease (such as insulin-dependant diabetes mellitus) Intra-uterine growth retardation Oligohydramnios HIV-positive women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A, 07, 001<br>Pregnant women at term with a baby in breech presentation who will have an external cephalic version. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relation between maternal mood state and thyroid function during end gestation and successful external version of fetal breech position |  | during external cephalic version | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the relation between neonatal thyroid parameters at delivery and successful external version, the effect of successful version on hipdysplasia |  | at the time of delivery, at the age of 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breech Presentation, External Cephalic version, Thyroid Function Tests
Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Photo Avaluation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINBACK Sweet Flower.

Official Title
-----------------
Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower

Conditions
-----------------
Hygiene

Intervention / Treatment
-----------------
* Drug: Dermacyd PH_DETINBACK (Lactic Acid)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Phototype Skin II and III; Integral skin test in the region; Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; Exclusion criteria: Lactation or gestation Use of Antiinflammatory and/or immunosuppression drugs 15 days before the selection; Diseases which can cause immunity decrease, such as HIV, diabetes; Use of drug photosensitizer; History of sensitivity or irritation for topic products; Active cutaneous disease which can change the study results; History of photodermatosis active; Family or personal antecedent of cutaneous photoinduced neoplasias; Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and queratoses actinium; Intense solar exposure in the study area; Use of new drugs or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Dermacyd PH_DETINBACK (Lactic Acid) | Drug: Dermacyd PH_DETINBACK (Lactic Acid)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type. |  | Throughout the study |
Cervicitis by Iontophoresis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to: Investigate effect of iontophoresis on managing uterine cervicitis.

Official Title
-----------------
Effectiveness of Iontophoresis in Managing Uterine Cervicitis

Conditions
-----------------
CERVICITIS

Intervention / Treatment
-----------------
* Device: IONTOPHORESIS
* Drug: ORAL ANTIBIOTIC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients have vaginal discharge. All patients have irregular vaginal bleeding, especially after sexual intercourse. All patients have dyspareunia. All patients have Lower abdominal pain. Group A: 20 women will receive oral medication (antibiotic zesrosin) and hot water with antiseptic. Group B: 20 women will receive medication by iontophoresis (antibiotic ceftriaxone) and hot water with antiseptic. Exclusion Criteria: Patients with a history of hypersensitivity or adverse reactions associated with the delivered drug in (ceftriaxone). Patients with prior medical histories of cardiac arrhythmias or hypercoagulability should not receive the procedure near cardiac pacemakers and superficial blood vessels. In the vicinity of embedded wires, stapes, orthopedic implants, and areas of skin with lesions and impaired sensation. It either should not be used or used with extreme caution during pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EXPERIMENTAL ARM<br> | Device: IONTOPHORESIS<br>* The process of increasing the penetration of drugs into the skin by application of an electric current<br>|
| Active Comparator: CONTROL ARM<br> | Drug: ORAL ANTIBIOTIC<br>* Oral Antibiotic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in change in Urine Analysis and Cervical swab results in both groups | Presence of Pus Cells in Urine Analysis and a Positive Cervical swab results | 7 Days difference between pre and post tests |